Dear Gordon J, Beaumont Claire, Roberts Andrew, Squillaci Bianca, Thomas Steve, Nash Mike, Fraser Donna
Structural Identification, Toxicokinetics & Biotransformation, PTS DMPK, GlaxoSmithKline R&D, Park Road, Ware, Hertfordshire, SG12 0DP, UK.
Bioanalysis. 2011 Jan;3(2):197-213. doi: 10.4155/bio.10.186.
Understanding the metabolism of a novel drug candidate in drug discovery and drug development is as important today as it was 30 years ago. What has changed in this period is the technology available for proficient metabolite characterization from complex biological sources. High-efficiency chromatography, sensitive MS and information-rich NMR spectroscopy are approaches that are now commonplace in the modern laboratory. These advancements in analytical technology have led to unequivocal metabolite identification often being performed at the earliest opportunity, following the first dose to man. For this reason an alternative approach is to shift from predicting and extrapolating possible human metabolism from in silico and nonclinical sources, to actual characterization at steady state within early clinical trials. This review provides an overview of modern approaches for characterizing drug metabolites in these early clinical studies. Since much of this progress has come from technology development over the years, the review is concluded with a forward-looking perspective on how this progression may continue into the next decade.
在药物发现和药物开发过程中,了解新型候选药物的代谢情况如今与30年前一样重要。在此期间发生变化的是可用于从复杂生物来源高效表征代谢物的技术。高效色谱法、灵敏的质谱法和信息丰富的核磁共振光谱法是现代实验室中如今常见的方法。分析技术的这些进步使得在首次给人体用药后,往往能尽早明确鉴定出代谢物。因此,一种替代方法是从通过计算机模拟和非临床来源预测及推断可能的人体代谢,转向在早期临床试验中对稳态下的实际特征进行表征。本综述概述了在这些早期临床研究中表征药物代谢物的现代方法。由于多年来的大部分进展都来自技术发展,综述最后以前瞻性的视角探讨了这种进展如何可能持续到下一个十年。